BOARD OF DIRECTORS

Mikko Mannerkoski, MSc (Tech), MBA

Mikko Mannerkoski is the Chairman of the Board of Aranda. Mikko brings Aranda over 20 years of experience in helping create and execute on value-creation strategies. He initially worked in investment banking advising major corporate and private equity clients in mergers & acquisitions and capital market transactions. He rose to a leadership position in what was at the time a leading corporate finance advisory in Northern Europe before setting on an entrepreneurial track. For the past 10 years Mikko has been active in the life-science field as a founder and shareholder in a handful of companies in the US and in Finland that work in radiation oncology, immune-oncology, antibody-drug conjugates and diagnostics. Mikko has a M.Sc. from Helsinki University of Technology (currently Aalto University, Department of Bioproducts and Biosystems) and M.B.A. in finance from the Helsinki School of Economics with studies at the Ross School of Business of the University of Michigan. Currently Mikko is CFO at Rappta Therapeutics Ltd.


Erkki Tenhunen

Erkki Tenhunen is a Board member of Aranda. Erkki brings Aranda 25 years of expertise in high technology start-up companies, fundraising, business development and commercialization of drug development and MedTech projects. He started his career in life-sciences by co-founding Contral Pharma that developed a drug against alcoholism. The company was later listed on the Helsinki Stock Exchange subsequently sold to a US acquirer in a public tender offer. Erkki has later co-founded several companies developing radiation therapy equipment and anti-cancer pharmaceutical technologies. Currently Erkki is head of Business Development at Rappta Therapeutics Ltd.


Milla Koistinaho, PhD, Adjunct professor in Neurobiology

Milla Koistinaho is a founder and a Board member of Aranda. Milla has over 15 years of experience in commercializing biomedical inventions and developing business models especially in the therapeutic areas of CNS diseases and oncology. She has been a member of founding team in three start-up companies in Finland. For 9 years Milla has served as a founding CEO at Medeia Therapeutics Ltd and been responsible for IPR generation, leading research programs and partnerships, executing financing rounds and leading business development actions. Milla has also been CSO and CEO in Cerebricon Ltd serving clients in pharmaceutical development. She is well networked internationally and she has also worked as a postdoctoral researcher in biopharmaceutical projects at Eli Lilly and Company in the USA. Milla holds Adjunct Professorship in neurobiology at University of Eastern Finland. She has a PhD degree from the same university. Milla gained her PhD thesis in collaboration with Stanford University and Scios Inc., California, USA. Currently Milla is the Director of Life Sciences at the Helsinki Innovation Services Ltd, Finland. Currently Milla is the Director of Life Sciences at the Helsinki Innovation Services Ltd, Finland.